Treatment with Janssen’s Erleada plus androgen deprivation therapy (ADT) resulted in a 25 percent reduction in the risk of death compared with placebo plus ADT in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.
Pfizer’s oral Janus kinase 1 (JAK1) inhibitor abrocitinib hit the primary endpoint in a second Phase III study in patients 12 and older with moderate to severe atopic dermatitis.
New data from TWILIGHT – a Phase IV independent trial funded by AstraZeneca – showed that in patients at high-bleeding risk who underwent PCI and completed three months of dual antiplatelet therapy, Brilinta monotherapy (90 mg twice daily) reduced the risk of BARC (Bleeding Academic Research Consortium) type 2, 3 or 5 bleeding compared to Brilinta plus low-dose aspirin after 12 months.
An investigational medicine in late-stage development by Jazz Pharmaceuticals hit the mark in treating cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy.
Enanta Pharmaceuticals Inc. announced top-line results from the biotechnology company’s ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).
Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.
Paris-based GenSight Biologics reported the first group of data from Week 96 of the company’s RESCUE Phase III clinical trial.
Mallinckrodt plc announced positive top-line results from the global biopharmaceutical company’s pivotal Phase 3 clinical trial of the investigational StrataGraft regenerative tissue.
Researchers Develop New Class of Lung Cancer Drugs
Chemotherapy, Clinical Trials, Drug-resistant tumors, Francis Crick Institute, G12C KRAS inhibitors, IGF1R Pathway, KRAS gene, KRAS Mutations, Lung adenocarcinoma, Lung Cancer, mTOR Pathway, Mutations, R&D, Researchers, Science Translational Medicine, The Institute of Cancer Research (ICR)Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.
Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.